NCT03490786View on ClinicalTrials.gov

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 16, 2017

Primary Completion Date

August 9, 2017

Study Completion Date

October 2, 2017

Conditions
Feeding and Eating Disorders
Interventions
DRUG

GT-001

PK, PD Study to Determine Safety of Escalating Doses of GT-001

Trial Locations (1)

92780

Orange County Research Center, Tustin

Sponsors
All Listed Sponsors
lead

Gila Therapeutics, Inc.

INDUSTRY

NCT03490786 - A Dose Escalating Study to Assess the Safety and Tolerability of GT-001 | Biotech Hunter | Biotech Hunter